BPI 002

Drug Profile

BPI 002

Alternative Names: BPI-002

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BeyondSpring Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer

Most Recent Events

  • 19 May 2017 BeyondSpring plans a phase I trial for Cancer
  • 28 Apr 2017 BeyondSpring intends to file an IND application for Cancer
  • 08 Mar 2017 BeyondSpring Pharma has pending patents for BPI 002 in USA and other jurisdictions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top